Showing 2641-2650 of 5909 results for "".
- Johnson & Johnson Vision Receives Approval in Japan for First Drug-Releasing Combination Contact Lens for Vision Correction and Allergic Eye Itchhttps://modernod.com/news/johnson-johnson-vision-receives-approval-in-japan-for-first-drug-releasing-combination-contact-lens-for-vision-correction-and-allergic-eye-itch/2479010/Johnson & Johnson Vision announced approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the first and only vision correction contact lens that relieves allergic eye itch: Acuvue Theravision with Ketotifen. The lens contains ketotifen, an H1 histamine receptor antagonis
- Steady Growth, New Technologies Will Drive Retinal Surgery Device Market to $1.36 Billion by 2026https://modernod.com/news/steady-growth-new-technologies-will-drive-retinal-surgery-device-market-to-1-36-billion-by-2026/2479005/The retinal surgical device market is expected to total more than $1.14 billion in 2021, with revenue rising to nearly $1.36 billion in 2026, according to a Market Scope report. Retina surgery device sales are driven almost entirely by vitrectomy, a procedure which involves removal of the
- VSY Biotechnology Signs Agreement with Wakamoto Pharmaceutical on Intraocular Lens Productshttps://modernod.com/news/vsy-biotechnology-signs-agreement-with-wakamoto-pharmaceutical-on-intraocular-lens-products/2479003/VSY Biotechnology announced an agreement with Wakamoto Pharmaceutical to provide new treatments for cataract surgeries in Japan. The agreement includes a licensing arrangement with Wakamoto Pharmaceutical to develop and launch IOLs in Japan. “We’re very excited to work with Wak
- National Eye Institute Launches Data Portal for Macular Degeneration Researchhttps://modernod.com/news/national-eye-institute-launches-data-portal-for-macular-degeneration-research/2478992/The National Eye Institute (NEI) Data Commons now enables researchers to access data from patients with macular degeneration who participated in the Age-related Eye Disease
- CooperVision: Clariti 1 day Becomes First Net Plastic Neutral Contact Lens in the UShttps://modernod.com/news/coopervision-clariti-1-day-becomes-first-net-plastic-neutral-contact-lens-in-the-us/2478971/To provide an easy way for eye care professionals and their patients to be more sustainable, CooperVision announced a partnership with Plastic Bank that makes its clariti 1 day family the first net plastic neutral contact lenses.1 Plastic Bank is a social enterprise that builds
- Lilly’s Bamlanivimab, Etesevimab Cut Hospitalizations, Deaths in High-Risk COVID-19 Patientshttps://modernod.com/news/lillys-bamlanivimab-etesevimab-cut-hospitalizations-deaths-in-high-risk-covid-19-patients/2478961/Eli Lilly reported new phase 3 results demonstrating that the antibody cocktail containing bamlanivimab and etesevimab significantly reduced COVID-19-related hospitalizations and deaths in high-risk patients recently diagnosed with SARS-CoV-2 infection. “These positive results reinforce our
- Adverum Announces Shortened Timelines and Development Path for ADVM-022 Intravitreal Gene Therapy in Wet AMDhttps://modernod.com/news/adverum-announces-shortened-timelines-and-clear-development-path-for-advm-022-intravitreal-gene-therapy-in-wet-amd/2478955/Adverum Biotechnologies announced that it has gained alignment with the FDA on the clinical development path for ADVM-022, an investigational single, in-office intravitreal (IVT) injection gene therapy for the treatment of wet age-related macular degeneration (AMD
- Santen EMEA Leads Awareness Campaign to Prioritize Their Glaucoma During the Pandemichttps://modernod.com/news/santen-emea-leads-awareness-campaign-to-prioritize-their-glaucoma-during-the-pandemic/2478942/Santen, along with a group of patient advocacy groups across Europe, is leading a multi-channel awareness campaign to encourage patients to prioritize their glaucoma during the pandemic. The on-and-offline campaign, w
- Hydrus Microstent Now First MIGS Device With 5-Year Pivotal Trial Datahttps://modernod.com/news/hydrus-microstent-now-first-migs-device-with-5-year-pivotal-trial-data/2478937/Ivantis, developer of the novel Hydrus Microstent, announced the first release of 5-year follow-up data from its HORIZON pivotal trial. This milestone represents the longest continuous follow-up of a MIGS device pivotal trial. The 5-year HORIZON data demonstrated the Hydrus Microstent̵
- New Survey Assessment Finds Debilitating Impact of Thyroid Eye Disease (TED) on Quality of Life Continues Beyond Acute Disease into Chronic Phasehttps://modernod.com/news/new-survey-assessment-finds-debilitating-impact-of-thyroid-eye-disease-ted-on-quality-of-life-continues-beyond-acute-disease-into-chronic-phase/2478913/Horizon Therapeutics announced results of a new Thyroid Eye Disease (TED) quality of life assessment presented at the North American Neuro-Ophthalmology Society (NANOS) 2021 Virtual Annual Meeting. Findings demonstrate that TED not only has a significant burden on patients during the acute (activ